Overview

Customizing First Line Chemotherapy in Advanced Non-Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The study aims at piloting the concept of customization of chemotherapy based on molecular markers in patients with stage IIIB (with pleural effusion) and IV with performance status ≤ 2 with pathologically proven non-small cell lung cancer (NSCLC). The study will not test or compare individual regimen but rather it will test the approach of customization concept as a whole. The results of this pilot study will help in designing more definitive trials in our patient population.
Phase:
Phase 2
Details
Lead Sponsor:
National Guard Health Affairs
Treatments:
Cisplatin
Docetaxel
Gemcitabine